Kazia Therapeutics LTD 6-K Filing

Key Financial Figures

• $0.01 — , the "Shares"), at a purchase price of $0.01 per Share, and (ii) pre-funded warrants
• $4.9999 — Ordinary Shares, at a purchase price of $4.9999 per Pre-Funded Warrant. Each Pre-Funded
• $0.0001 — ble for one ADS at an exercise price of $0.0001 per ADS underlying the Pre-Funded Warra
• $7.50 — arrants have an exercise price equal to $7.50 per ADS, or 150% of the offering price
• $46.5 m — hange for net proceeds of approximately $46.5 million, after deducting placement agent'
• $35 million — ("MVLS") remained below the minimum of $35 million required for continued listing on The N
• $2.5 million — s stockholders' equity in excess of the $2.5 million requirement for continued listing on Th

Filing Documents

• d81135d6k.htm (6-K) — 14KB
• 0001193125-25-309627.txt ( ) — 15KB

Forward-Looking Statements

Forward-Looking Statements This Report of Foreign Private Issuer on Form 6-K may contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by the use of words such as "may," "will," "estimate," "future," "forward," "anticipate," or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the intended use of proceeds from the Private Placement, the anticipated extension of the Company's cash runway into the second half of 2028 following completion of the private placement, the Company's ability to maintain listing on The Nasdaq Capital Market, including the Company's ability to regain compliance with Nasdaq's continued listing standards, and the Company's future expectations, plans and prospects. Such statements are based on Kazia's current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: related to market and other conditions, associated with clinical and preclinical trials and product development, including the risk that preliminary or interim data may not reflect final results, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia's Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under appli

View Full Filing

View this 6-K filing on SEC EDGAR